Cannabis poisoning children is no longer a rare event in New York State. A new report from the New York State Department of Health has found something startling. Emergency department visits linked to cannabis exposure among children aged 0 to 4 have climbed so sharply that cannabis now rivals, and in recent years has overtaken, the combined number of visits caused by Tylenol, aspirin and other common over the counter painkillers.

The findings come from the Department’s Statewide Planning and Research Cooperative System. They paint a troubling picture of what happens when a commercialised cannabis market expands into everyday life. According to coverage first reported by The Drug Report, cannabis related poisoning has become the second most common cause of emergency department visits among toddlers. It is also the leading cause of poisoning related hospital admissions in that age group.

The Scale of Cannabis Exposure in Young Children

The report tracked cannabis related poisoning emergency visits across New York State from 2016 to 2024. Statewide, these visits rose 98 per cent in that period. They climbed from 1,205 to 2,387 a year. But the sharpest change by far was among the very youngest patients.

Cannabis poisoning children aged 0 to 4 increased at a rate few public health officials expected. The visit rate per 100,000 residents in that age group rose 3,736 per cent, from 0.6 in 2016 to 22.9 in 2023. No other age group came close to that pace of change. Hospital discharges tell a similarly alarming story. Cannabis related poisoning admissions among toddlers surged more than 1,600 per cent over the same period. By 2021, this age group recorded the highest hospitalisation rate of any age bracket in the state.

Outpacing the Medicine Cabinet

Perhaps the most striking element of the report is its direct comparison with medicines long considered the default household hazard. Health officials found that cannabis exposure in young children matched the combined total of emergency visits linked to Tylenol, aspirin and nonsteroidal anti inflammatory drugs in 2022. It then exceeded that combined figure by roughly 100 cases in both 2023 and 2024.

By 2024, cannabis had climbed to become the second most common poisoning diagnosis among children under five presenting at emergency departments. It trailed only a broad category covering a wide range of other medicated products. Among all cannabis related visits in this age group that year, 72.2 per cent ended in treatment and release, while 27.8 per cent required inpatient admission. Cannabis related visits ranked as the leading cause of poisoning admissions to hospital among toddlers. They were also the second most common cause of treat and release cases.

A Commercial Market, Not an Accident of Nature

None of this happened in a vacuum. New York State’s cannabis landscape has shifted dramatically since the Compassionate Care Act established a medical programme in 2014. Federal legalisation of hemp followed in 2018. Then came the Marihuana Regulation and Taxation Act in 2021, which opened the door to a regulated adult use market. As availability has expanded, so has the range of cannabis products designed to look, taste and smell like ordinary treats.

Edible cannabis products are a significant driver of this trend. Many are packaged to resemble sweets, biscuits or fizzy drinks. These are precisely the kind of items that catch a curious toddler’s eye. Young children explore their world by putting things in their mouths. Their smaller body size also means even a modest dose carries an outsized risk. When an industry designs products that mimic sweets and markets them at scale, unintentional paediatric exposure becomes a predictable outcome rather than a freak accident.

Disparities Across Communities

The report also documented stark differences across demographic groups and regions. Black, Hispanic, Native American and multiracial communities experienced disproportionately high rates of cannabis related emergency visits and hospital admissions. Rural counties in western and central New York recorded some of the highest visit rates statewide. So did urban boroughs including the Bronx, Brooklyn and Manhattan. Medicaid recipients accounted for between 35 and 45 per cent of related visits and discharges, pointing to underlying socioeconomic disparities in who bears the brunt of this trend.

Stopping Cannabis Poisoning Children Before It Starts

Health officials have proposed safe storage guidance, childproof packaging and public education campaigns. These measures treat cannabis as a fixture of family life to be managed carefully, rather than treating its growing presence in homes as the problem itself. Cannabis poisoning children at this scale did not exist before commercialisation reshaped the market. Packaging tweaks and storage tips do not reverse that shift. They only attempt to soften its edges.

The clearest protective step for families is straightforward. Cannabis products do not belong in homes where young children live. For policymakers, the data offers a case for treating child cannabis exposure as a warning sign, not a manageable side effect of legalisation. Genuine prevention, not damage control dressed up as safety messaging, remains the surest way to keep the youngest New Yorkers safe from an industry that keeps expanding into their homes.

Source: thedrugreport